Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed highly experienced US biotech executive Dr Ellen Feigal as a Non-Executive Director of PTX. Dr Feigal is currently a Partner and Head of the Biologics practice at NDA Partners, where she leads efforts in designing and executing product development regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology.

In a decorated career, Dr Feigal was formerly Executive Medical Director, Global Development, at US biotech giant Amgen; Senior Vice President of Research and Development at the California Institute for Regenerative Medicine; and Chief Medical Officer at Insys Therapeutics. She directed the National Cancer Institute’s (NCI) Division of Cancer Treatment and Diagnosis after serving as Deputy Director, and was a senior investigator in the Cancer Therapy Evaluation Program. Dr. Feigal earned an MD at UC Davis, completed an internal medicine residency at Stanford, and a hematology/oncology fellowship at UC San Francisco.

This prominent appointment comes at a time when Prescient is expanding the PTX-100 trial in preparation for a Phase 2 trial off the back of the Phase 1b trial results, which showed a wealth of positive data – including two complete responses in patients with relapsed and refractory (r/r) Peripheral T-cell Lymphoma (PTCL). The company has also made significant progress with their CellPryme and OmniCAR platforms. 

Dr Feigal added, “I am excited to join the board of Prescient at this critical phase in the Company’s journey. I look forward to working with the team to leverage my experience and networks to guide the business through the next phase of its growth, in particular the formative stage of clinical development of PTX-100 and the development of its novel cell therapy platforms within this burgeoning and rapidly evolving field.”

New data to be presented at prestigious conference

Prescient Therapeutics also announced to the market that the prestigious International Society of Cell & Gene Therapy (ISCT) has accepted two Prescient abstracts that will be showcased at the annual meeting in Paris, France from 31 May to 3 June 2023. The ISCT brings together clinicians, regulators, researchers, technologists, and industry partners with a shared vision to translate cell and gene therapy into safe and effective therapies to improve patients’ lives worldwide. The annual conference attracts more than 2,700 cell and gene therapy experts from 60 countries.

Prescient researchers will present new preclinical data on both its next-gen modular, controllable CAR platform, OmniCAR, and its cell therapy enhancement platform, CellPryme. Both abstracts will also be published in the next issue of Cytotherapy, the official journal of the ISCT. The journal publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell and gene therapy.

Prescient’s CEO and Managing Director, Steven Yatomi-Clarke said, “To have not one but two abstracts accepted by this prestigious conference is testament to the quality and novelty of our science, and also exemplifies how both the OmniCAR and CellPryme platforms are positioned at the forefront of cell therapy utility and innovation.

To stay up to date with Prescient’s news and announcements, register your details on the investor portal.

Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.

Past performance is not a reliable indicator of future performance.